The Supervisory Board of Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026. With this appointment, Medios gains an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies.
Stefan Bauerreis previously served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the Europe region and CFO for Germany. He possesses extensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies. Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, stated that with Stefan Bauerreis, the company is gaining a proven financial expert with extensive experience in internationally positioned SDAX and MDAX companies who combines operational excellence with strategic foresight.
Stefan Bauerreis expressed his enthusiasm for the new role, stating he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he will contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally, in the best interest of shareholders and employees. The appointment comes as Medios prepares for several important events in the 2026 financial year, including the Metzler Small Cap Days 2026 in Frankfurt, TP ICAP Midcap Conference 2026 in Paris, and the company's Annual General Meeting 2026 in June.
Medios is a leading provider of Specialty Pharma in Europe, with locations in Germany, the Netherlands, Belgium and Spain. The company supports key partners in the supply chain with innovative solutions and intelligent services, focusing on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies. More information on individualized medicine is available at https://app.medios.group/en/individualizedmedicine. Medios AG is Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange and included in the SDAX selection index. Additional company information can be found at https://www.medios.group.
